학술논문
PCN300 - Switching to A 6-Monthly Triptorelin Formulation for Prostate Cancer (Pca) Reduces Patient–Nhs Interactions and Hospital Resource use: Real World Evidence (Rwe) from Project Deserve (Decapeptyl Service Evaluation)
Document Type
Abstract
Author
Source
In Value in Health November 2015 18(7):A483-A483
Subject
Language
ISSN
1098-3015